Last mentioned: Feb 20, 2026
Candel Public Offering
Candel Therapeutics prices $100M public offering at $5.45 per share.
Trial Data Release
Grail shares slide as NHS-Galleri trial misses primary endpoint for late-stage cancer reduction.
GDP Release
U.S. government scheduled to release Q4 GDP growth figures at 8:30 AM ET.
Grail Earnings
Grail reports Q4 and Full Year 2025 financial results, beating revenue and EPS estimates.
US equity futures signaled a positive open on Friday as investors shifted focus toward the release of fourth-quarter GDP figures. Following a lackluster Thursday session, the market is looking for confirmation of economic resilience while monitoring individual movers like Grail and Candel Therapeutics.
This page surfaces every story mentioning Candel Therapeutics across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Candel Therapeutics was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |